Abstract: The present application includes a method of preparing silicon nanocrystals (Si-NCs) comprising combining silica particles with magnesium and heating said combination under conditions to form Si-NCs, wherein the silica particles are obtained using sol gel chemistry.

Abstract: A nanotip, is fabricated by modifying a precursor nanotip having an apex and a shank by applying an electric field in the presence of a reactive gas to perform field-assisted etching wherein atoms are preferentially removed from the shank by chemical interaction with the reactive gas, and controlling the reactive gas pressure and/or tip voltage to vary the electric field so as to promote field evaporation of apex atoms during fabrication of the nanotip and thereby control the overall profile of the resulting nano-tip. The method permits shaping of the overall tip profile.

Abstract: A new set of branched nanowire or nanotree structures and their fabrication process. Some structures have one or more of the following distinctions from other branched nanowires: (1) the trunk and branch diameter and branching number density can be changed along the trunk's length; (2) the branch's azimuthal direction can be controlled along the trunk's length; (3) the branch's diameter can be modulated along its length; (4) the crystal orientation and branches of the ensemble of nanowires can be aligned on a non-epitaxially matched substrate. The structures are made by a geometrically controlled kinetic growth method.

Abstract: The invention is directed to methods for extracting phosvitin from egg yolk involving contacting the egg yolk or egg yolk protein granules with a solution having a salt concentration of about 10% to form a mixture; optionally, heating the mixture; adjusting the pH of the mixture to separate phosvitin from other proteins; recovering the phosvitin. The phosvitin extract may be dephosphorylated and hydrolyzed to produce phosvitin phosphopeptides.

Abstract: The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes.

Abstract: Described herein are compositions having a peptide sequence that includes at least one bone targeting moiety, wherein the bone targeting moiety is bonded to the peptide sequence by a linker, wherein the peptide sequence is calcitonin, and wherein the composition is neutral or a pharmaceutically acceptable salt or ester thereof. In one aspect, calcitonin inhibits or slows osteoclast mediated resorptive bone loss. The compounds described herein can be used in a number of therapeutic applications including treating or preventing conditions associated with bone loss, which include, but are not limited to, osteoporosis, Paget's disease, osteolytic tumors, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Osteoarthritis, osteopenia, and hypercalcemia. Also described herein are the methods of making these compositions that prevent or treat conditions associated with bone loss and methods of preventing bone fractures.

Abstract: Phosphoranimide-metal catalysts and their role in C—O bond hydrogenolysis and hydrodeoxygenation (HDO) are disclosed. The catalysts comprise of first row transition metals such as nickel, cobalt and iron. The catalysts have a metal to anionic phosphoranimide ratio of 1:1 and catalyze C—O bond hydrogenolyses of a range of oxygen-containing organic compounds under lower temperature and pressure conditions than those commonly used in industrial hydrodeoxygenation.

Abstract: Phosphoranimide-metal catalysts are disclosed. The catalysts comprise first row transition metals such as nickel, cobalt or iron. The hydrocarbon-soluble catalysts have a metal to anionic phosphoranimide ratio of 1:1, have no inactive bulk phase and no dative ancillary ligands, and are active for a range of commercially important reductive transformations. A method of synthesis of these catalysts by reduction of a precursor of these catalysts is also disclosed.

Abstract: Phosphoranimide-metal catalysts and their role in hydrogenation and hydrosilylation are disclosed. The catalysts comprise first row transition metals such as nickel, cobalt or iron. The catalysts have a metal to anionic phosphoranimide ratio of 1:1. This disclosure presents a process for catalytic hydrogenation and hydrosilylation of a range of unsaturated organic compounds under lower temperature and pressure conditions than conditions associated with industrial hydrogenation and hydrosilylation.

Abstract: The invention relates generally to methods and compositions for the cryopreservation and/or vitrification of tissue including articular cartilage and the preparation of said tissue for clinical or research use, including but not limited to joint replacement and the treatment and prevention of osteoarthritis.

Abstract: An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a Campylobacter organism. There is also provided an antibody or antisera against the compound, having particular use to diagnose the presence of an infection caused by a Campylobacter organism.

Abstract: There is provided a process for the reduction of one or more amide moieties in a compound comprising contacting the compound with hydrogen gas and a transition metal catalyst in the presence or absence of a base under conditions for the reduction an amide bond. The presently described processes can be performed at low catalyst loading using relatively mild temperature and pressures, and optionally, in the presence or absence of a base or high catalyst loadings using low temperatures and pressures and high loadings of base to effect dynamic kinetic resolution of achiral amides.

Abstract: The invention is directed to adhesives derived from animal or plant proteins, particularly canola and spent hen proteins. The adhesives are prepared by extracting the proteins by pH shifting; and either treating the extracted proteins with urea or sodium dodecyl sulfate, or polymerizing the proteins to form a protein-polymer conjugate. The invention is also directed to a wood based product comprising pieces of wood based material joined or consolidated with the adhesives.

Abstract: There is described a pixel sensor converter for an image sensor array. In particular, a pixel sensor converter comprising: a delta-sigma converter comprising a modulator and a decimator. In some examples, the modulator is configured to be in communication with a detector, such as a photo-detector, and is configured to sample an analogue signal received from a detector at a particular sampling rate. The modulator is further configured to provide a bit stream of a particular bit rate. The provided bit stream corresponds to a sampled analogue signal. The decimator is in communication with the modulator, and is configured to receive and modify a bit stream provided from the modulator in order to provide a digital output signal. The provided digital output signal is representative of an analogue signal received at the modulator, but having a reduced bit rate than a corresponding bit stream provided by the modulator.

Abstract: A method for single-cycle selection of aptamers is provided. More specifically, a method comprising single-cycle selection of aptamers for proteins blotted on a membrane is provided. In some embodiments, the present methods can comprise a deoxyribonuclease I (DNase I) mediated aptamers selection strategy that may be capable of isolating strong binding aptamers for target proteins from a crude protein extract. Aptamers selected using the present method are further provided. More specifically, the presently selected aptamers may be thermally stable, modifiable and easily produced through single-cycle synthesis process. The present aptamers may provide unique affinity reagents for use in diagnosing and detecting infectious disease (for example Hepatitis B), for research and biochemical studies (e.g. into molecular mechanisms). Further, the present aptamers may be utilized to develop unique assays or kits for clinical application, such as monitoring disease treatment and outcome.

Abstract: This invention provides monoclonal antibodies that recognize hENT1. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and/or prophylactic in disorders associated with aberrant hENT1 expression and/or activity.

Abstract: Novel CMUT architectures are provided permitting independent addressability of both top and bottom CMUT electrodes. CMUT top electrodes are connected in strips along the x-direction, while CMUT bottom electrodes are connected in strips along the y-direction. In an embodiment, 3D imaging can be performed with an N×N 2D array using only N transmit channels and N receive channels.

Abstract: The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy.

Abstract: This disclosure presents an advanced design of an energy harvester that utilizes a piezoelectric element to convert vibration to electricity. The advanced design is based on a fixed-fixed folded beam. An aqua regia wet etching and PZT sol-gel deposition/patterning processes can be used to manufacture the energy harvester.

Abstract: The invention is directed to thermoplastics derived from feathers. The thermoplastics are prepared by blending whole feathers or portions thereof with a plasticizer in an amount ranging from about 20 wt to about 40 wt % and a reducing agent in an amount ranging from about 1 wt % to about 5 wt % to form a mixture; and either extruding the mixture to form an article, or pressing the mixture into a film at an elevated temperature.